Forecasting Stories
Approximately 38.0% of Danimer Scientific's shares are owned by institutional investors, such as insurance companies. Insider ownership in Danimer Scientific pertains to the equity held by the company's officers, directors, leadership team relatives, or anyone with access to non-public information. For our latest analysis of Danimer, including current ownership details, please refer to our recent ownership diagnostics report.
Primary Takeaways
Danimer Scientific, a player in the Specialty Chemicals industry, has shown a promising uptick in its stock price today with a price change of 0.02 and a price percent change of 3.7%.over three months ago at Macroaxis By Rifka Kats |
Every cloud has a silver lining, and the recent dip in Smart Global Holdings' stock price may just be the investment opportunity savvy traders have been waiting for. This NASDAQ-listed company, a key player in the Semiconductors industry, has seen its stock price fluctuate between a 52-week low of $12.66 and a high of $27.88. Despite the recent downturn, the company's fundamentals remain strong.
over three months ago at Macroaxis By Rifka Kats |
Palisade Bio has a beta of 3.6342, indicating potential outperformance if the market rises. Conversely, in a declining market, it may underperform. Beta helps investors gauge if Palisade Bio's movements align with the broader market and assess its volatility or risk relative to a selected benchmark.
over three months ago at Macroaxis By Gabriel Shpitalnik |
In the world of investing, it's often said that the trend is your friend until it ends. This seems to be the case with Helen of Troy (USA Stocks: HELE), a company in the Consumer Defensive sector, specifically within the Household Durables category. Despite the company's strong fundamentals, such as an EPS Estimate of 9.72 for next year and a current year EPS Estimate of 8.75, the market has shown signs of a potential downturn.
over three months ago at Macroaxis By Raphi Shpitalnik |
TherapeuticsMD has a beta of 0.7063, indicating its returns are highly responsive to market fluctuations. As the market swings, the company's returns are expected to correspondingly adjust. The beta metric assists investors in determining whether TherapeuticsMD's movements align with the broader market and its relative volatility or risk.
over three months ago at Macroaxis By Rifka Kats |
Citigroup has a beta of 1.2633, indicating it's expected to outperform the market when it rises. Conversely, if the market declines, Citigroup is likely to underperform. The beta indicator reveals how Citigroup's movements align with the broader market and its relative volatility or risk.
over three months ago at Macroaxis By Rifka Kats |
Investors considering Nano Nuclear (USA Stocks: NNE) may find the company's recent insider trading trends intriguing. With a significant accumulation distribution of 394.5K and a daily trading volume of 1.8M, there is a clear indication of strong investor interest and activity in the stock. Despite a high standard deviation of 14.8, indicating potential volatility, the company's positive Jensen Alpha of 4.63 suggests a potential for superior risk-adjusted returns.
over three months ago at Macroaxis By Vlad Skutelnik |
Relay Therapeutics Inc has a beta of 2.6294, indicating that it is likely to outperform the market when it rises. Conversely, it may underperform during market downturns. The beta value helps investors gauge if Relay Therapeutics Inc's movements align with the broader market, and assess its volatility or risk level relative to the chosen benchmark.
over three months ago at Macroaxis By Raphi Shpitalnik |
In the world of investing, fortune favors the bold. Nano Dimension (NASDAQ: NNDM), a key player in the Technology Hardware, Storage & Peripherals industry, is poised for a potentially strong performance in July. With a 52-week high of $3.35 and a current typical day price of $2.7, the company's stock shows promising signs of growth.
over three months ago at Macroaxis By Rifka Kats |
Assure Holdings Corp, currently valued at $0.41 per share, appears overvalued considering its modest future projections. Approximately 17.0% of the company's shares are owned by insiders, including officers, directors, and relatives of the leadership team, as well as those privy to non-public information. For a comprehensive analysis of Assure, including its current ownership structure, refer to our latest ownership diagnostics.
Major Takeaways
Assure Holdings Corp. (IONM) is showing promising signs for investors looking for growth potential in the healthcare equipment industry.over six months ago at Macroaxis By Rifka Kats |